title: A case of myelodysplastic syndrome developed blastic crisis of chronic myelogenous leukemia with acquisition of major BCR/ABL.
abstract: We describe a rare case of myelodysplastic syndrome that developed chronic myelogeneous leukemia with acquisition of Philadelphia chromosome. The major BCR/ABL transcript was confirmed by molecular analysis. Shortly thereafter, the patient showed transformation to blastic crisis. Hematological remission was achieved after 3 months of treatment with imatinib mesylate. The patient relapsed with additional chromosomal abnormalities and the disease became refractory to the treatment. Acquisition of the Philadelphia chromosome is an infrequent event in myelodysplastic syndrome, and the addition of this change to the initial genetic abnormality that caused MDS may have been associated with the accelerated clinical course of this patient.
authors.affiliation: Department of Internal Medicine, Asahikawa City Hospital, 1-65, Kinseicho 1 chome, Asahikawa, Hokkaido, Japan. masahiro.onozawa@nifty.ne.jp
authors.forename: Masahiro
authors.initials: M
authors.lastname: Onozawa
authors.forename: Takashi
authors.initials: T
authors.lastname: Fukuhara
authors.forename: Mutsumi
authors.initials: M
authors.lastname: Takahata
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Yamamoto
authors.forename: Takayoshi
authors.initials: T
authors.lastname: Miyake
authors.forename: Isao
authors.initials: I
authors.lastname: Maekawa
mesh_terms: D000368:Aged; D001549:Benzamides; D001752:Blast Crisis / Q000235:genetics / Q000473:pathology*; D002892:Chromosomes, Human, Pair 22; D002899:Chromosomes, Human, Pair 9; D019008:Drug Resistance, Neoplasm; D017809:Fatal Outcome; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D006801:Humans; D000068877:Imatinib Mesylate; D017404:In Situ Hybridization, Fluorescence; D007621:Karyotyping; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics* / Q000473:pathology*; D008297:Male; D009190:Myelodysplastic Syndromes / Q000235:genetics / Q000473:pathology*; D010879:Piperazines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D012333:RNA, Messenger / Q000032:analysis; D012074:Remission Induction; D014178:Translocation, Genetic
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D012333:RNA, Messenger; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl